Bel­gian biotech Du­a­lyx en­ters Treg field with $44M for 2024 clin­i­cal en­try

A young Bel­gian biotech aims to en­ter the clin­ic next year with a new Treg for au­toim­mune dis­eases, and now has $44 mil­lion in fi­nanc­ing to do so.

The Se­ries A will help Du­a­lyx take its first Treg can­di­date, DT-001, in­to a Phase I study in the sec­ond half of 2024, CEO Wouter Ver­ho­even told End­points News on Mon­day. Their first pro­gram is an an­ti­body go­ing af­ter TNF re­cep­tor 2, an im­muno­sup­pres­sive and “key im­mune mod­u­la­tor,” Ver­ho­even said, and they’ve yet to choose which au­toim­mune in­di­ca­tions it will go af­ter first.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER